Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study.
Shiratori S, Fukushima K, Onishi Y, Doki N, Goto T, Okada M, Nakamae H, Maeda Y, Kato K, Ishikawa T, Kondo T, Toyosaki M, Ikeda T, Uchida N, Maki A, Shimada F, Tajima T, Stefanelli T, Teshima T.
Shiratori S, et al.
Int J Hematol. 2024 Dec;120(6):705-716. doi: 10.1007/s12185-024-03850-9. Epub 2024 Oct 3.
Int J Hematol. 2024.
PMID: 39361234
Free PMC article.
Clinical Trial.